× ×ª×× × ×ª×¨×פ×
××רש×
| ××× ×× ×× × ×ספ××
|
|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
B01AC
Platelet aggregation inhibitors excluding heparin
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
פ××× - PER OS
|
| צ×רת ××× ××
|
×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 12/01/2017
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
|
|
|
ש×××ש ×ס×
-
|
×ס×רת ××××× ×ס×
- ×. ×תר××¤× ×××××¨× ×ª×× ×ª× ×××פ×× ××××× ×××××ר ×-NYHAâ (New York Heart Association) ×-Class III ×××¢×× ×ס××× ××תר ×××¥ ×× ×¨×××ª× ×¢××¨×§× Group I ×שר ××ר×ת ××פ×× ×¢× ×ª×¨×פ×ת ××שפ×ת ×-Endothelin receptor antagonists ×/×× ××שפ×ת PDE-5 ×¢×××× × ×צ××× ×ר×× ×ª×¤×§×××ת 3.
- ×. ×ת××ת ×××פ×× ×תר××¤× ×××××¨× ×ª××× ×¢× ×¤× ××ר××ª× ×©× ×× ×× ××××§× ×××ת ××××× ×©××× ××××× ×××××ת ר××× ×× ××××× ×קר×××××××× ×× ××××× ×××פ×× × ×רץ ×××× ×× ××××× ×××ר×ר××ת ××× ×× ×× ××××× ×קר×××××××ת ××××× ×× ××××× ×××××ת ר××× ××××× ×× ××××× ×××פ×× × ×רץ ××××× ×× ××××× ×ר××××××××××.
- ×. ×××©× ×××פ×× ×תר××¤× ×××××¨× ×××¢×©× ×¢× ×¤× ××¨×©× ×©× ××××× ×××××ת ר××× ×× ××××× ×קר×××××××× ×× ××××× ×××פ×× × ×רץ ×××× ×× ××××× ×××ר×ר××ת ××× ×× ×× ××××× ×קר×××××××ת ××××× ×× ××××× ×××××ת ר××× ××××× ×× ××××× ×××פ×× × ×רץ ××××× ×× ××××× ×ר××××××××××.
- ×. × ××ª× ××ת××× ××פ×× ×תר××¤× ×××××¨× ×××§×¨× ×× ××ª× ×××ת ×ר××ת×ת ××××ש×ת ת×ש×ר ××××× ×××¨× ××¡× ×¤×¨×ק××××× ×××ת ××שר ××××× ×¡××× ×-NYHA Class III ×××¢×× ×××¢× ×ר×ק ××××× ×-6 ×ק×ת ×× ××× ×-400 ××ר×× ×-2 ×××ק×ת ×¢×ק××ת.
- ×. ×ש ××××× ×¢ ×ש××××× ×ª×¨×פ×ת ××× ×××¤× ××× ×¤×¢× ×תר××¤× ××××ת ×רק ×¢× ××ש××× ×××פ×× ××, ××¢××ר ×××פ×× ×תר××¤× ××רת, ×××¢× ××צ××× ×××××:
- 1. ×××ש××× ×©× ××פ×× ×-Sildenafil × ××ª× ×××ס××£ ××קר×× × ××ר×× Iloprost ×××× ××צ×× ×× Selexipag ×× Bosentan ×× Ambrisentan ×× Macitentan
- 2. ×××ש××× ×©× ××פ×× ×-Bosentan ×× Ambrisentan ×× Macitentan × ××ª× ×××ס××£ ××קר×× × ××ר×× Iloprost ×××× ××צ×× ×× Selexipag ×× Sildenafil
|
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
ת××× ×ª ×ר×××
ת×ר×× ×¢××××: 15/05/19
ACTELION
×פ×ר×× - Uptravi
true
השינוי האחרון נעשה בֹ־23 ביוני 2023 ב־18:08
